Proteros and SUPERGEN Enter Into an Integrated Lead Discovery Agreement
News Feb 04, 2011
Proteros Biostructures GmbH (Proteros) announced that it has entered into an agreement with SuperGen Inc., under which Proteros will collaborate on the discovery of small molecule lead compounds against a specific target of interest.
Under the agreement, Proteros will deploy its integrated lead discovery platform that seamlessly links structural biology, screening of a tailor-made compound and fragment library, compound profiling and medicinal chemistry activities aimed at rapid fragment evolution and lead finding.
Cony D’Cruz Chief Business Officer and President Proteros US, Inc. stated, “We are very pleased to be selected by SuperGen to work with them on an exciting target. We believe our structure guided approach is particularly suited to accelerate SuperGen’s efforts in this target area.”
“Rapid fragment evaluation will synchronize well with our CLIMB® discovery platform” said Dr. Michael McCullar, Senior Vice President Strategy and Discovery Operations “We are excited to be working with Proteros”.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE